.jpeg)
2026-03-10 05:17:26
Brigatinib as a targeted therapy demonstrates significant efficacy in treating Neurofibromatosis Type 2 (NF2), capable of reducing tumor volume and improving hearing function, providing new hope for patients unable to benefit from surgery or radiation.
2026-03-10 01:38:34
Goserelin, as a GnRH analog, is widely used for prostate cancer, breast cancer, and gynecological diseases, but may cause side effects like hot flashes and bone density loss. 2025 clinical guidelines recommend light, nutritious, balanced diet with high protein and calcium, avoiding spicy and processed foods. Special populations need personalized management to enhance treatment tolerance and quality of life.
2026-03-10 01:22:25
Breakthrough research published in "Genes & Immunity" (2025) identifies folate metabolism-related gene CYP26A1 as a clinical immune target for colorectal cancer. Multi-omics analysis and experimental validation reveal CYP26A1's role in promoting tumor proliferation, metastasis, and immunosuppressive microenvironment, offering new precision treatment directions for patients.
2026-03-06 05:41:28
Decoding Inavolisib’s breakthrough in PIK3CA-mutant HR+/HER2- breast cancer: INAVO120 trial data, quality-of-life preservation, and expansion to HER2+ disease.
2026-03-06 05:19:40
Compare Romiplostim (subcutaneous) and Eltrombopag (oral) for ITP, highlighting administration, onset time, side effects, and clinical decision factors to optimize personalized therapy.
2026-03-06 04:55:21
Decoding asciminib (Asciminib)'s targeting of the ABL myristoyl pocket, its breakthrough role in treating CML resistance, pharmacokinetics, and clinical advantages for informed patient decisions.
2026-03-06 04:15:06
Eplerenone is commonly prescribed for long-term management of hypertension and heart failure but requires regular monitoring of potassium and kidney function. This article analyzes its safety, necessity, and key precautions for sustained use.
2026-03-04 07:32:53
Explore whether Ixazomib (Ninlaro) requires long-term use for Multiple Myeloma. Analyze its critical role in induction and maintenance therapy, the impact of long-term adherence on extending progression-free survival, and expert advice on side effect management and personalized discontinuation strategies.
2026-02-28 06:38:41
Master Regorafenib (Stivarga) dosing: low-fat breakfast, fixed timing, dose escalation strategy for optimal efficacy and reduced side effects in liver and colorectal cancer.
2026-02-28 03:31:21
Isatuximab (Sarclisa) is a CD38-targeting monoclonal antibody approved for relapsed/refractory and newly diagnosed Multiple Myeloma. Its mechanism involves apoptosis induction, ADCC immune killing, and enzymatic inhibition. Clinical data confirms extended Progression-Free Survival (PFS) and improved MRD negativity with combination regimens. This guide covers IV infusion protocols, Infusion-Related Reaction (IRR) management, and patient quality of life insights for optimized treatment decisions.
2026-02-26 03:14:05
Erlotinib,also known as Tarceva,is a classic drug of the epidermal growth factor receptor(EGFR)tyrosine kinase inhibitor(TKI)family and has a milestone in the precision treatment of lung cancer.Its core indication is non-small cell lung cancer(NSCLC)patients carrying EGFR sensitive mutations.With the advantages of precise targeting and definite efficacy,it effectively breaks the limitations of traditional chemotherapy,promotes the new era of lung cancer treatment from"extensive chemotherapy"to"precise targeting",and brings longer survival and better quality of life to countless advanced lung cancer patients.
2026-02-09 05:42:31
Upatinib (Rift) ®） As an oral JAK inhibitor, it has been approved for various immune-mediated inflammatory diseases such as rheumatoid arthritis, psoriatic arthritis, atopic dermatitis, ulcerative colitis, Crohn's disease, etc. The target population is mainly moderate to severe patients, especially suitable for adults who have insufficient response to traditional treatment, need oral convenience, or have poor injection compliance.
